Partnership & Exhibition

We would like to invite your Company to support the organization of this important event by contributing as a Partner or Exhibitor, applying for packages and other Partnership Opportunities and/or space at the Exhibition Area.

We encourage you to contact the Sponsorship Coordinator to discuss the best sponsorship package to meet your budget and needs. If you have specific requirements or desired outcomes linked to your sponsorship, we would be happy to discuss the optimal package to suit your organization.

PARTNERSHIP PROSPECTUS

For further details on the opportunities available please contact:

CESN-CASN 2024 Symposium Secretariat

Mrs. Pavlína Krátká
Industry Liaison Officer

e-mail: kratka@guarant.cz
cell phone:+420 777 663 398

Compliance

We are pleased to inform you that the 6th Central European Symposium on Nephrology – 10th Czech–Austrian Symposium on Nephrology
has been recognized as:
Compliant with the MedTech Europe Code of Ethical Business Practice.

This decision is posted on www.ethicalmedtech.eu.

Partners

PLATINUM PARTNER

Astellas Pharma is a global pharmaceutical company based in Japan. Its main goal is to improve the health and quality of life of patients through innovative medicinal products.

Astellas focuses on research, development, manufacturing, and distribution of pharmaceutical products in various therapeutic areas, including urology, transplantation, oncology, gastroenterology, Women's Health and others.

Astellas has a strong presence worldwide and operates in more than 70 countries. Its research and development centers are located in different parts of the world, including Japan, the United States, Europe, and Asia. These centers focus on the discovery and development of new medicinal products that can bring innovative solutions for patients.

Astellas emphasizes collaboration with academic institutions, scientific organizations, and other partners in the field of research and development. This collaboration allows for the sharing of knowledge, experiences, and resources, leading to the discovery of new treatment options and improvement of healthcare.

Astellas also values sustainability and corporate social responsibility. It is committed to reducing its impact on the environment, supporting community projects, and initiatives in the areas of health and education. Astellas strives to be a good partner for patients, healthcare professionals, and the communities in which it operates.

Astellas employs thousands of people who share a passion for health and innovation. The company creates an environment that fosters employee development, creativity, and collaboration. Astellas believes that a strong team is key to achieving success and making a difference for patients.

GOLD PARTNERS

About Chiesi

Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.

The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com.

Teva was founded in 1901 in Israel and has since grown into one of the largest pharmaceutical companies in the world. In the field of transplantology, Teva focuses on the development and distribution of immunosuppressive drugs, which are crucial for preventing the rejection of transplanted organs. Teva's portfolio includes several key products that are widely used around the world:

Tacforius (tacrolimus): A significant immunosuppressive drug commonly used in liver and kidney transplants. Tacrolimus provides effective control over the immune system and minimizes the risk of organ rejection.
Equoral (cyclosporine): One of the first immunosuppressive drugs widely accepted by the medical community. Cyclosporine helped transform organ transplantation from an experimental procedure into standard medical practice.
Myfenax (mycophenolate mofetil): This drug is often used in combination with other immunosuppressants to increase their effectiveness and reduce the risk of transplant rejection.

In addition to drug development, Teva also focuses on providing support to healthcare professionals and patients. The company organizes educational programs, conferences, and workshops that help spread knowledge about the latest advances in transplantology. Teva is dedicated to its mission of improving the lives of transplant patients by delivering affordable medications. Teva has become a key player in the field of transplantology. Through research and development in generic medicines, patients around the world have better chances for successful recovery and long-term healthy life after transplantation.

SILVER PARTNER

AstraZeneca is a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following: Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease.

BRONZ PARTNERS

Takeda Pharmaceutical Company Limited, a global leader in the biopharmaceutical sector, focuses on delivering life-transforming treatments. With strong roots in Japan, Takeda operates in over 80 countries. Our core therapeutic areas include Oncology, Rare Diseases, Neuroscience, Gastroenterology, Plasma-Derived Therapies, and Vaccines. We emphasize innovation, a patient-centric approache, and sustainable practices. Our commitment to science and societal well-being drives our mission to improve health and ensure better future for patients worldwide.

Our commitment to the transplant community is backed by our deep understanding of the complexities of managing post-transplant CMV infection. We are dedicated to supporting endeavors in post-transplant care and seek to translate the community needs into science that helps CMV patients preserve and improve life after transplant.

For further information please visit www.takeda.com.

As part of Thermo Fisher Scientific, we offer products and services to advance the science of transplant diagnostics. Our solutions help transplant labs and clinical teams provide personalized care across the patient experience.

Dr. Paul Terasaki founded One Lambda^™ in 1984 to develop tests to improve how laboratories match and monitor transplant recipients and donors. Since then, our HLA typing and antibody detection assays have been trusted by transplant laboratories worldwide. Clinicians also rely on data from our patient monitoring tests to make important decisions about post-transplant therapies.

Transplantation is life-changing for recipients, and clinical diagnostics play a vital role in supporting all phases of treatment. Through our commitment to scientific innovation, product quality, patient advocacy, and excellent customer service, we are helping the transplant community raise the standard of care and improve patient and family outcomes.